Compare BridgeBio Pharma Inc (BBIO) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Under Armour Inc Class A — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Under Armour Inc Class A trades at $5.24 (market cap $2.48B). The key difference: BridgeBio Pharma Inc is far larger — about 6.7× Under Armour Inc Class A's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| BBIO | UA | |
|---|---|---|
Market Cap | $16.61B | $2.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $7.88 |
52-Week Low | $47.29 | $3.96 |
Enterprise Value | $18.16B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Under Armour (UA) trades at $5.925, down 5.2% with bearish technical signals. The company reported mixed Q2 2026 results with an earnings beat but faces revenue declines and negative profitability metrics. Recent news highlights lowered fiscal 2027 revenue outlook due to softer consumer demand in key markets. Cash flow remains negative with significant operational challenges.
The outlook remains challenging with declining revenue trends and negative margins. While analyst consensus shows mixed sentiment, the stock faces headwinds from competitive pressures and execution risks. Investment opportunity exists only for those betting on a successful turnaround despite current fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
